BIRC5 and cancer: Given that Survivin and Bcl‐2 constitute two pivotal pro‐survival mechanisms fostering therapeutic resistance in cancer cells, our revelation that 2,4‐DTBP concurrently downregulates both proteins becomes particularly consequential.